Cell And Gene Therapies Are Altering Patient Expectations, Says CGT Catapult CEO

Patients Will Expect Their Condition To Be Taken Away, Rather Than Treated

 
• By Chloe Kent

The Cell and Gene Therapy Catapult was established in 2012 and exists to advance the growth of the UK’s CGT industry, supporting companies in this space throughout product development and beyond. In Vivo caught up with CEO Matthew Durdy, who took over the role from Keith Thompson in 2020, to learn what the first three years of his tenure have taught him and how he sees the future of advanced therapies progressing.

Headshot of Matthew Durdy
Matthew Durdy took over as CGT Catapult CEO as the COVID-19 pandemic began in early 2020 • Source: Shutterstock

Matthew Durdy, CEO of the Cell and Gene Therapy Catapult, told In Vivo “two obvious things” have changed in the advance therapies space since he took over the role in spring 2020.

“I walked straight in to the COVID-19 crisis,” he said. “So the first year was all about maintaining an organization through COVID-19. The pandemic was both disruptive and positive. It injected a huge amount of capital into the system, but some of the investment environment has been difficult – as well as COVID-19 you’ve got the political uncertainties which have knocked things around, alongside the changes in interest rates and investment profiles

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from In Vivo